228 related articles for article (PubMed ID: 22180309)
1. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
Kanakkanthara A; Northcote PT; Miller JH
Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
[TBL] [Abstract][Full Text] [Related]
2. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
Kanakkanthara A; Wilmes A; O'Brate A; Escuin D; Chan A; Gjyrezi A; Crawford J; Rawson P; Kivell B; Northcote PT; Hamel E; Giannakakou P; Miller JH
Mol Cancer Ther; 2011 Aug; 10(8):1419-29. PubMed ID: 21653684
[TBL] [Abstract][Full Text] [Related]
3. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
Kanakkanthara A; Eras J; Northcote PT; Cabral F; Miller JH
Curr Cancer Drug Targets; 2014; 14(1):79-90. PubMed ID: 24245693
[TBL] [Abstract][Full Text] [Related]
4. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
5. Exploring the interaction of Peloruside-A with drug resistant αβII and αβIII tubulin isotypes in human ovarian carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV
J Biomol Struct Dyn; 2021 Apr; 39(6):1990-2002. PubMed ID: 32241247
[TBL] [Abstract][Full Text] [Related]
6. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells.
Kanakkanthara A; Rawson P; Northcote PT; Miller JH
Pharm Res; 2012 Nov; 29(11):3022-32. PubMed ID: 22584948
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
Wilmes A; O'Sullivan D; Chan A; Chandrahasen C; Paterson I; Northcote PT; La Flamme AC; Miller JH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):117-26. PubMed ID: 20848285
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.
Hamel E; Day BW; Miller JH; Jung MK; Northcote PT; Ghosh AK; Curran DP; Cushman M; Nicolaou KC; Paterson I; Sorensen EJ
Mol Pharmacol; 2006 Nov; 70(5):1555-64. PubMed ID: 16887932
[TBL] [Abstract][Full Text] [Related]
10. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
[TBL] [Abstract][Full Text] [Related]
11. Zampanolide, a Microtubule-Stabilizing Agent, Is Active in Resistant Cancer Cells and Inhibits Cell Migration.
Field JJ; Northcote PT; Paterson I; Altmann KH; Díaz JF; Miller JH
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467385
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
[TBL] [Abstract][Full Text] [Related]
13. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells.
Das V; Miller JH
Brain Res; 2012 Dec; 1489():121-32. PubMed ID: 23085090
[TBL] [Abstract][Full Text] [Related]
14. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
Zhou J; Cheng SC; Luo D; Xie Y
Biochem Biophys Res Commun; 2001 Feb; 280(5):1237-42. PubMed ID: 11162660
[TBL] [Abstract][Full Text] [Related]
15. Peloruside, laulimalide, and noscapine interactions with beta-tubulin.
Gajewski MM; Alisaraie L; Tuszynski JA
Pharm Res; 2012 Nov; 29(11):2985-93. PubMed ID: 22733149
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae.
Hanna R; Maass DR; Atkinson PH; Northcote PT; Teesdale-Spittle PH; Bellows DS; Miller JH
Mol Biosyst; 2014 Jan; 10(1):110-6. PubMed ID: 24161989
[TBL] [Abstract][Full Text] [Related]
17. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.
Pineda O; Farràs J; Maccari L; Manetti F; Botta M; Vilarrasa J
Bioorg Med Chem Lett; 2004 Oct; 14(19):4825-9. PubMed ID: 15341932
[TBL] [Abstract][Full Text] [Related]
18. The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [³H]peloruside A.
Nguyen TL; Xu X; Gussio R; Ghosh AK; Hamel E
J Chem Inf Model; 2010 Nov; 50(11):2019-28. PubMed ID: 21028850
[TBL] [Abstract][Full Text] [Related]
19. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Gan PP; Kavallaris M
Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.
Begaye A; Trostel S; Zhao Z; Taylor RE; Schriemer DC; Sackett DL
Cell Cycle; 2011 Oct; 10(19):3387-96. PubMed ID: 21926482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
